Lactobacillus Plantarum NCHBL-004 Composition for Weight and Glucose Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for obesity and metabolic diseases, such as non-alcoholic fatty liver disease, often come with significant side effects and there is a need for therapeutic strategies with novel mechanisms that offer effective anti-obesity and metabolic disease-improvement effects with minimal side effects.

Innovation Solution

A pharmaceutical composition containing Lactobacillus plantarum NCHBL-004 strain or its culture, which inhibits adipocyte differentiation and lowers blood glucose levels, is used for the prevention, treatment, or alleviation of metabolic diseases like obesity and diabetes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current pharmaceutical treatments for obesity and metabolic diseases are used, then effective anti-obesity and metabolic disease-improvement effects are achieved, but significant side effects occur

Engineering Contradiction:

ImproveeffectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces probiotic bacteria (Lactobacillus plantarum NCHBL-004) as an intermediary substance that mediates between diet and metabolic health. These bacteria act as a biological modulator that influences adipocyte differentiation and glucose metabolism without directly interfering with neural satiety pathways, thereby achieving metabolic benefits without the neurological side effects of conventional drugs

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/chemical direct-action mechanism of conventional obesity drugs (which directly stimulate brain satiety receptors or block fat absorption) with a biological mechanism involving probiotic bacteria. The bacteria produce metabolites and modulate gut microbiota that indirectly influence metabolism through hormonal and inflammatory pathways, substituting direct pharmacological action with biological modulation

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If conventional obesity drugs are used to induce satiety, then weight loss is achieved, but dependency and tolerance issues arise

Engineering Contradiction:

Improveweight loss efficacyVSAvoiddependency risk

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The probiotic bacteria utilize the body's existing metabolic pathways and gut microbiota ecosystem to achieve weight loss effects. The bacteria self-regulate their population and metabolite production based on host physiological conditions, creating a sustainable modulation of metabolism without external pharmacological intervention, thereby eliminating dependency risks

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent changes the fundamental parameter of intervention from direct neural or hormonal manipulation to microbial community modulation. By altering the composition and function of gut bacteria, the system naturally influences metabolic parameters such as energy expenditure, fat storage, and glucose regulation through bacterial metabolites and immune system interaction, avoiding the tolerance and dependency issues of direct pharmacological agents

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If direct action on brain satiety pathways is used, then appetite suppression is achieved, but neurological side effects occur

Engineering Contradiction:

Improveappetite controlVSAvoidneurological side effects

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent introduces gut microbiota as an intermediary system that bridges dietary intake and metabolic regulation without direct brain involvement. The probiotics modulate gut hormones (such as GLP-1, PYY) and inflammatory cytokines that indirectly influence appetite and metabolism through peripheral pathways, avoiding direct neural interference and its associated side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent substitutes direct central nervous system action with peripheral metabolic modulation through probiotic bacteria. The bacteria act on gut epithelial cells, immune cells, and metabolic tissues to regulate energy balance and glucose metabolism, replacing the need for direct brain-targeted pharmacology with a distributed peripheral biological mechanism

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively inhibits weight gain and reduces blood glucose levels, providing a safe and effective solution for metabolic diseases.

Implementation Method 1

Lactobacillus plantarum NCHBL-004 strain or a culture thereof for the prevention, treatment, or alleviation of metabolic diseases

Methodology Applied

Scientific EffectProbiotic action: Fermentation

Data Source

PatentUS20250325607A1Composition for preventing, treating, or improving metabolic diseases comprising lactobacillus plantarum nchbl-004 strain or culture medium thereof

Publication Date: 2025.10.23 IND FOUND OF CHONNAM NAT UNIV

AI summary

The present invention relates to a composition for preventing, treating, or improving metabolic diseases comprising Lactobacillus plantarum NCHBL-004 strain or a culture medium thereof, and the composition not only inhibits adipocyte differentiation and inhibits weight gain, but also exhibits a blood sugar lowering effect, and can thus be effectively used for preventing, treating, or improving metabolic diseases.